This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Schwartz JM, Wolford JL, Thornquist MD et al. Severe gastrointestinal bleeding after hematopoietic cell transplantation, 1987–1997: incidence, causes, and outcome. Am J Gastroenterol 2001; 96: 385–393.
Arai S, Margolis J, Zahurak M et al. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002; 8: 155–160.
Nademanee A, Schmidt GM, Parker P et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 1995; 86: 1228–1234.
Van Lint MT, Uderzo C, Locasciulli A et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998; 92: 2288–2293.
Ricordi C, Tzakis AG, Zeevi A et al. Reversal of graft-versus-host disease with infusion of autologous bone marrow. Cell Transplant 1994; 3: 187–192.
Passweg JR, Orchard K, Buergi A et al. Autologous/syngeneic stem cell transplantation to treat refractory GvHD. Bone Marrow Transplant 2004; 34: 995–998.
Pusic I, Pavletic SZ, Kessinger A et al. Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease. Bone Marrow Transplant 2002; 29: 709–710.
Weiss L, Slavin S . Prevention and treatment of graft-versus-host disease by down-regulation of anti-host reactivity with veto cells of host origin. Bone Marrow Transplant 1999; 23: 1139–1143.
Kuwana M, Kaburaki J, Wright TM et al. Induction of antigen-specific human CD4(+) T cell anergy by peripheral blood DC2 precursors. Eur J Immunol 2001; 31: 2547–2557.
Hoffmann P, Ermann J, Edinger M et al. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196: 389–399.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Khan, S., Moreb, J. Reversal of severe graft-versus-host disease after nonmyeloablative matched unrelated donor stem cell transplant by infusion of backup autologous peripheral blood stem cells. Bone Marrow Transplant 36, 267–268 (2005). https://doi.org/10.1038/sj.bmt.1705033
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705033